Clinical Trial Update: Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL) [Phase 1]

View source ↗

Summary

Phase 1 study of Micro Needle Array-Doxorubicin (MNA-D) for Cutaneous T-cell Lymphoma has completed, evaluating a microneedle-based delivery of doxorubicin.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma

Drugs mentioned

• Micro Needle Array-Doxorubicin (MNA-D) (doxorubicin)

Snippet

Sponsor: Falo, Louis, MD | Conditions: Cutaneous T Cell Lymphoma | Phase 1 | Status: COMPLETED